Redmile Group, LLC sold FATE

April 20, 2026 · Form 4 insider transaction

Redmile Group, LLC sold 8,977,624 shares of Fate Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as j and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
8,977,624
Price
$0.00
Total value
N/A
Role
SecurityCommon Stock
Transaction codeJ: J
Transaction dateApril 20, 2026
Filing dateApril 22, 2026
Shares owned after0
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

In connection with an internal reorganization of RedCo II Master Fund, L.P. ("RedCo II"), which is one of the private investment vehicles managed by Redmile Group, LLC ("Redmile"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the "SPVs"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the "Common Stock"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green.; The reported securities were directly owned by RedCo II.; Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR